Publications by authors named "Brendan D Curti"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

384

Total Likes

48

Extended Reach

34,589

Social Features

16
I
Intratumoral oncolytic virus V937 plus ipilimumab in patients with advanced melanoma: the phase 1b MITCI study.
Brendan D Curti, Jon Richards, John R Hyngstrom, Gregory A Daniels, Mark Faries, Lynn Feun, Kim A Margolin, Sigrun Hallmeyer, Mark Grose, Yiwei Zhang

J Immunother Cancer· December 2022

Videos about Article: user

1 15

View All Article and Social Media Activity
C
Checkpoint Immunotherapy for Melanoma - Offering Hope for Cure.
Brendan D Curti

N Engl J Med· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Systemic immunostimulation induces glucocorticoid-mediated thymic involution succeeded by rebound hyperplasia which is impaired in aged recipients.
Craig P Collins, Lam T Khuat, Gail D Sckisel, Logan V Vick, Christine M Minnar, Brendan D Curti

Front Immunol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1 study of triple-targeted therapy with BRAF, MEK, and AKT inhibitors for patients with BRAF-mutated cancers.
Alain P Algazi, James Moon, Christopher D Lao, Bartosz Chmielowski, Kari L Kendra, Brendan D Curti

Cancer· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bempegaldesleukin Plus Nivolumab in Untreated Advanced Melanoma: The Open-Label, Phase III PIVOT IO 001 Trial Results.
Adi Diab, Helen Gogas, Shahneen Sandhu, Georgina V Long, Paolo A Ascierto, Brendan D Curti

J Clin Oncol· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SALVO: Single-Arm Trial of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal Melanoma.
Lisa A Kottschade, Gregory Russell Pond, Anthony J Olszanski, Yousef Zakharia, Evidio Domingo-Musibay, Brendan D Curti

Clin Cancer Res· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cancer's Dark Matter: Lighting the Abyss Unveils Universe of New Therapies.
Bernard A Fox, Walter J Urba, Shawn M Jensen, David B Page, Brendan D Curti

Clin Cancer Res· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 dose-escalation study of SEA-CD40: a non-fucosylated CD40 agonist, in advanced solid tumors and lymphomas.
Andrew L Coveler, David C Smith, Tycel Phillips, Brendan D Curti, Sanjay Goel

J Immunother Cancer· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient-reported tolerability of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk stage III-IV melanoma in phase III trial E1609.
Laurie E McLouth, Yue Zheng, Stephanie Smith, F Stephen Hodi, Uma N Rao, Brendan D Curti

Qual Life Res· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced -Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134.
Michael B Atkins, Sandra J Lee, Bartosz Chmielowski, Ahmad A Tarhini, Gary I Cohen, Brendan D Curti

J Clin Oncol· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in patients with advanced solid tumors.
Charles M Rudin, Hardev S Pandha, Matthew Zibelman, Wallace L Akerley, Kevin J Harrington, Brendan D Curti

J Immunother Cancer· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase II, Single-arm Trial of Sunitinib and Erlotinib in Advanced Renal Cell Carcinoma.
Zizhen Feng, Brendan D Curti, David I Quinn, John M Strother, Zunqiu Chen

Clin Genitourin Cancer· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
For Ethical Fundraising from Patients, Respect them as Partners.
Brendan D Curti

Narrat Inq Bioeth· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trough levels of ipilimumab in serum as a potential biomarker of clinical outcomes for patients with advanced melanoma after treatment with ipilimumab.
Yoshinobu Koguchi, Noriko Iwamoto, Takashi Shimada, Shu-Ching Chang, John Cha, Brendan D Curti

J Immunother Cancer· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma.
Adi Diab, Scott S Tykodi, Gregory A Daniels, Michele Maio, Brendan D Curti

J Clin Oncol· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma.
Amod A Sarnaik, Omid Hamid, Nikhil I Khushalani, Karl D Lewis, Theresa Medina, Brendan D Curti

J Clin Oncol· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recent Advances in the Treatment of Melanoma.
Brendan D Curti, Mark B Faries

N Engl J Med· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enhancing clinical and immunological effects of anti-PD-1 with belapectin, a galectin-3 inhibitor.
Brendan D Curti, Yoshinobu Koguchi, Rom S Leidner, Annah S Rolig, Elizabeth R Sturgill

J Immunother Cancer· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HDAC inhibition prevents transgene expression downregulation and loss-of-function in T-cell-receptor-transduced T cells.
Tamson V Moore, Gina M Scurti, Matthew DeJong, Siao-Yi Wang, Annika V Dalheim, Brendan D Curti

Mol Ther Oncolytics· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant anti-OX40 (MEDI6469) therapy in patients with head and neck squamous cell carcinoma activates and expands antigen-specific tumor-infiltrating T cells.
Rebekka Duhen, Carmen Ballesteros-Merino, Alexandra K Frye, Eric Tran, Venkatesh Rajamanickam, Brendan D Curti

Nat Commun· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Flt3 ligand augments immune responses to anti-DEC-205-NY-ESO-1 vaccine through expansion of dendritic cell subsets.
Nina Bhardwaj, Philip A Friedlander, Anna C Pavlick, Marc S Ernstoff, Brian R Gastman, Brendan D Curti

Nat Cancer· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02).
Adi Diab, Nizar M Tannir, Salah-Eddine Bentebibel, Patrick Hwu, Vassiliki Papadimitrakopoulou, Brendan D Curti

Cancer Discov· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Delayed immune-related events (DIRE) after discontinuation of immunotherapy: diagnostic hazard of autoimmunity at a distance.
Marcus A Couey, R Bryan Bell, Ashish A Patel, Meghan C Romba, Marka R Crittenden, Brendan D Curti

J Immunother Cancer· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel IL2Rβγ-Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors.
Salah-Eddine Bentebibel, Michael E Hurwitz, Chantale Bernatchez, Cara Haymaker, Courtney W Hudgens, Brendan D Curti

Cancer Discov· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition.
Elizabeth I Buchbinder, Janice P Dutcher, Gregory A Daniels, Brendan D Curti, Sapna P Patel

J Immunother Cancer· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis